Sarah Kathryn Rouan - Net Worth and Insider Trading

Sarah Kathryn Rouan Net Worth

The estimated net worth of Sarah Kathryn Rouan is at least $318 dollars as of 2024-04-27. Sarah Kathryn Rouan is the Director of Navidea Biopharmaceuticals Inc and owns about 8,350 shares of Navidea Biopharmaceuticals Inc (NAVB) stock worth over $318. Sarah Kathryn Rouan is also the Director of Viking Therapeutics Inc and owns about 0 shares of Viking Therapeutics Inc (VKTX) stock worth over $0. Details can be seen in Sarah Kathryn Rouan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Sarah Kathryn Rouan has not made any transactions after 2024-02-08 and currently still holds the listed stock(s).

Transaction Summary of Sarah Kathryn Rouan

To

Sarah Kathryn Rouan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Sarah Kathryn Rouan owns 2 companies in total, including Navidea Biopharmaceuticals Inc (NAVB) , and Viking Therapeutics Inc (VKTX) .

Click here to see the complete history of Sarah Kathryn Rouan’s form 4 insider trades.

Insider Ownership Summary of Sarah Kathryn Rouan

Ticker Comapny Transaction Date Type of Owner
NAVB Navidea Biopharmaceuticals Inc 2019-05-17 director
VKTX Viking Therapeutics Inc 2024-02-08 director

Sarah Kathryn Rouan Latest Holdings Summary

Sarah Kathryn Rouan currently owns a total of 2 stocks. Among these stocks, Sarah Kathryn Rouan owns 8,350 shares of Navidea Biopharmaceuticals Inc (NAVB) as of May 17, 2019, with a value of $318 and a weighting of 100%. Sarah Kathryn Rouan also owns 0 shares of Viking Therapeutics Inc (VKTX) as of February 8, 2024, with a value of $0 and a weighting of 0%.

Latest Holdings of Sarah Kathryn Rouan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
NAVB Navidea Biopharmaceuticals Inc 2019-05-17 8,350 0.04 318
VKTX Viking Therapeutics Inc 2024-02-08 0 74.31 0

Holding Weightings of Sarah Kathryn Rouan


Sarah Kathryn Rouan Form 4 Trading Tracker

According to the SEC Form 4 filings, Sarah Kathryn Rouan has made a total of 1 transactions in Navidea Biopharmaceuticals Inc (NAVB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Navidea Biopharmaceuticals Inc is the acquisition of 3,350 shares on May 17, 2019, which cost Sarah Kathryn Rouan around $4,891.

According to the SEC Form 4 filings, Sarah Kathryn Rouan has made a total of 2 transactions in Viking Therapeutics Inc (VKTX) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Viking Therapeutics Inc is the sale of 25,000 shares on February 8, 2024, which brought Sarah Kathryn Rouan around $701,250.

Insider Trading History of Sarah Kathryn Rouan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Sarah Kathryn Rouan Trading Performance

GuruFocus tracks the stock performance after each of Sarah Kathryn Rouan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Sarah Kathryn Rouan is -64.34%. GuruFocus also compares Sarah Kathryn Rouan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Sarah Kathryn Rouan within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Sarah Kathryn Rouan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Sarah Kathryn Rouan

Average Return

-23.08%

Average return per transaction

Outperforming Transactions

0%

0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -52.45 -64.34 -51.75 -23.08 5.44 -16.91
Relative Return to S&P 500(%) -53.5 -65.36 -60.87 -23.23 -15.19 -29.56

Sarah Kathryn Rouan Ownership Network

Ownership Network List of Sarah Kathryn Rouan

No Data

Ownership Network Relation of Sarah Kathryn Rouan


Sarah Kathryn Rouan Owned Company Details

What does Navidea Biopharmaceuticals Inc do?

Who are the key executives at Navidea Biopharmaceuticals Inc?

Sarah Kathryn Rouan is the director of Navidea Biopharmaceuticals Inc. Other key executives at Navidea Biopharmaceuticals Inc include Chief Financial Officer Craig Dais , director & 10 percent owner Scott John K Jr. , and Chief Regulatory Officer Michel Mikhail .

Navidea Biopharmaceuticals Inc (NAVB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Navidea Biopharmaceuticals Inc (NAVB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Navidea Biopharmaceuticals Inc (NAVB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Navidea Biopharmaceuticals Inc (NAVB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Navidea Biopharmaceuticals Inc Insider Transactions

No Available Data

Sarah Kathryn Rouan Mailing Address

Above is the net worth, insider trading, and ownership report for Sarah Kathryn Rouan. You might contact Sarah Kathryn Rouan via mailing address: 4995 Bradenton Avenue, Suite 240, Dublin Oh 43017.

Discussions on Sarah Kathryn Rouan

No discussions yet.